Key result
Melatonin treatment significantly increased the 14-day survival rate to 67.7% compared to 46.7% in the CVB3-infected control group and ameliorated myocardial injury.
Why the study?
Current therapeutic options for viral myocarditis are unsatisfactory, and the potential therapeutic effect of melatonin on viral myocarditis remains unknown.
Does melatonin ameliorate myocardial injuries in a mouse model of coxsackievirus B3-induced myocarditis?
Does melatonin ameliorate myocardial injuries in a mouse model of coxsackievirus B3-induced myocarditis?
Melatonin demonstrates protective effects against acute viral myocarditis in a preclinical mouse model by modulating apoptosis and autophagy.
Answers are grounded in this paper and cite their sources.
Caution against clinical use in viral myocarditis; animal data leave open human translation.
Current therapeutics options for viral myocarditis are unsatisfactory. Melatonin (MLT), a hormone secreted by the pineal gland and other organs, has protective effects on ischemic heart injury. However, the potential therapeutic effect of MLT on viral myocarditis is unknown. In this study, we investigated the protective effect of MLT on viral myocarditis in a mouse model of myocarditis infected with coxsackievirus B3 (CVB3) and explored the probable mechanisms. Mice with CVB3-induced myocarditis displayed inflammatory cell infiltration and interstitial edema. MLT treatment significantly ameliorated the myocardial injuries. In addition, the rate of autophagy changed, although apoptosis was inhibited in mouse hearts following treatment with MLT. These results suggest that MLT has a strong therapeutic effect on acute viral myocarditis, which is associated with changes in autophagy and apoptosis in the heart. Thus, MLT could be a promising novel therapeutic approach against viral myocarditis.
No takes yet. Share an insight, caveat, or question.
Sang et al. (2018) studied Coxsackievirus B3-induced myocarditis (n=150). Melatonin vs. CVB3 infection alone (PBS) was evaluated on Survival rate at 14 days (p=<0.05). Melatonin treatment significantly increased the 14-day survival rate to 67.7% compared to 46.7% in the CVB3-infected control group and ameliorated myocardial injury.
Synapse has enriched 10 related papers. Consider them for comparative context: